Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

"Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate" was originally created and published by ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...

Navi Mumbai: In a medical breakthrough at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, a 39-year-old Rijesh Nair, a ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

Researchers sought to determine whether patients with PMBCL may be able to forgo irradiation therapy during consolidation.

TOPLINE: Sjögren disease (SjD) presents three distinct phenotypes ― B-cell active with low symptom burden, high systemic ...

Brookline raised the firm’s price target on Caribou Biosciences (CRBU) to $34 from $26 and keeps a Buy rating on the shares. Caribou plans to ...